. A) Inter-assay correlation analysis for 168 cases; B) Bland-Altman plot for 168 cases showing estimated bias (mean difference in discriminant scores, red line) and 95% confidence interval (dashed lines); C) instrument-to-instrument correlation analysis for 21 cases; D) Bland-Altman plot for 21 cases showing estimated bias (mean difference in discriminant scores, red line) and 95% confidence interval (dashed lines)
Background
• The majority of metastases and death attributed to cutaneous melanoma (CM) occur in patients who are initially diagnosed with Stage I or Stage II disease. 1 • A 31-gene expression profile (GEP) test that provides a molecular classification associated with risk of metastasis has been validated and clinically available since 2013. 2, 3 • The test determines a low risk (Class 1) or high risk (Class 2) of metastasis within five years of the primary diagnosis of CM with an area of reduced confidence identified from the true positives and negatives from the training set.
• This study evaluated the analytical reliability and reproducibility of the 31-GEP test • We also report the technical experience of the test and the association of risk prediction with standard clinicopathologic factors linked to CM metastasis and death.
Methods
• Formalin-fixed paraffin-embedded tissue from primary melanoma tumors was successfully processed for 8,244 patients from 1,123 centers in the U.S. and Spain between March 2013 and June 2016 using the 31-GEP RT-PCR-based assay.
• Metastatic risk class was determined using a proprietary predictive modeling algorithm which provides two results: a binary classification of Class 1 (low risk) or Class 2 (high-risk) tumor biology, and a quantitative discriminant score from 0 to 1.0, for which 0.5 represents the cutoff score between the binary classes.
• Testing was repeated for a subset of the specimens to assess interassay variability and concordance of risk assignment.
• Quality control and multiple gene failures were assessed, and pathology reports were evaluated for all specimens to evaluate association of the test results with clinical and pathologic characteristics of the samples. 
Results

Conclusions
• The 31-GEP test demonstrates robust, reproducible and reliable performance in primary tumor FFPE specimens.
• Educational efforts in biopsy tissue conservation practices have yielded significant improvements in the rate of tissue received with adequate tumor nuclei content.
• Though high-risk (Class 2) molecular classification is associated with pathologic stage and other prognostic factors, a significant number of metastatic cases classified as low risk by anatomic staging are identified by the GEP.2,3
Disclosures
The proprietary GEP test is clinically available through Castle Biosciences as the DecisionDx ® -Melanoma test (www.SkinMelanoma.com). Reduction in required tumor content from >60% to >40% and improvements in biopsy tissue preservation 
Clinical reliability and reproducibility of a prognostic 31-gene expression profile test for cutaneous melanoma, and association of the test with standard clinicopathologic factors
